In just concluded meeting of Board of Directors , the Board approved and considered the following items: 1. Unaudited (Standalone and Consolidated) Financial Statements for the quarter ....

Gennex Laboratories reported unaudited Q2 FY26 standalone revenue from operations of Rs. 2,932.63 lakhs, up about 18.8% from Rs. 2,468.59 lakhs in Q2 FY25. Standalone net profit grew to Rs. 453.32 lakhs from Rs. 415.85 lakhs (~9% YoY). Half-year standalone revenue rose ~19.4% to Rs. 5,496.63 lakhs, while net profit was Rs. 868.27 lakhs vs Rs. 832.45 lakhs (~4.3% YoY). On a consolidated basis, Q2 revenue was Rs. 3,724.21 lakhs (up ~18%) with net profit of Rs. 551.15 lakhs; H1 consolidated revenue was Rs. 7,141.96 lakhs with net profit of Rs. 1,052.80 lakhs. EPS stood at Rs. 0.187 (standalone) and Rs. 0.207 (consolidated) for the quarter. The auditor (R Pugalia & Co.) issued a limited review report stating nothing came to their attention requiring disclosure under Listing Regulations. The company manufactures bulk drugs (Guaifenesin, Methocarbamol) and exports to countries including Vietnam, India, Colombia, Egypt, and others.